COVID-19 Outbreak Highlights Gaps in Indian Pharma’s Quality Management
Research Paper
March 16, 2020
Preview
The coronavirus outbreak has applied supply chain shocks to companies relying on China for their raw materials and key supplies. The outbreak has thrown questions of quality management and resilience into sharp relief for Indian pharma companies that could have significant repercussions on the supply of medicines globally. India is the largest provider of generic drugs globally, and generic drugs account for 20% of global exports in terms of volumes. This report explores the quality-management issues facing the pharmaceutical industry highlighted by disruptions in the global supply of medicine caused by the COVID-19 pandemic.
Read the full paper
Read the full paper
Provide your information for instant access to our research papers.
The content of this page is for informational purposes only and is intended for institutional professionals with the analytical resources and tools necessary to interpret any performance information. Nothing herein is intended to recommend any product, tool or service. For all references to laws, rules or regulations, please note that the information is provided “as is” and does not constitute legal advice or any binding interpretation. Any approach to comply with regulatory or policy initiatives should be discussed with your own legal counsel and/or the relevant competent authority, as needed.